Population and randomization: Enroll adults with type 2 diabetes or insulin resistance, stratified by baseline HbA1c and renal function. Randomize 1:1 to metformin XR versus IR, titrated per standard protocols. The XR-vs-IR comparison is justified by pooled RCT evidence showing no significant differences in HbA1c (MD 0.04%, 95% CI -0.05 to 0.13%), fasting plasma glucose (MD -0.03 mmol/L, 95% CI -0.22 to 0.15), or gastrointestinal adverse events (RR 1.09, 95% CI 0.93-1.29), while XR showed better compliance (80% vs 72%; 62%β81% after switching) .
Longitudinal biomarker panel (baseline, week 6, week 12, week 24): HbA1c, fasting glucose, fasting insulin with HOMA-IR, ALT/AST, serum B12, and body composition. HOMA-IR and insulin are included because a metformin-resveratrol-HMB combination reduced insulin from 62 to 43 Β΅U/mL and HOMA-IR from 29 to 19 in diabetic mice, though this is preclinical evidence with industry sponsorship (NuSirt Sciences) and requires human confirmation . ALT monitoring is warranted because uncontrolled NASH data (n=20, metformin 500 mg TID x 4 months) showed substantial transaminase reductions, e.g., ALT 152β52 in one patient, but without randomization or follow-up biopsy .
Safety monitoring: Measure serum B12 at baseline and 12 months given the 5.8% deficiency prevalence in metformin users versus 2.4% in non-users and 3.3% in non-diabetics (NHANES 1999-2006, n=575 metformin users, 1,046 non-users, 6,867 non-diabetics) . Monitor renal function given that in accumulation cases (n=12, mean pH 6.88, lactate 14.8 mmol/L), terminal metformin half-life was prolonged to 51.9 h in plasma and 43.4 h in erythrocytes, with detectability up to 13 days despite dialysis .
Analysis plan: Intention-to-treat, mixed-effects models for repeated measures with random intercepts per participant; primary endpoint is change in HbA1c at week 24; secondary endpoints are HOMA-IR, compliance, ALT, and B12. Pre-specify subgroup analyses by baseline renal function. Report both complete-case and multiple-imputation results given heterogeneous compliance.
Key limitations and blind spots: Prior RCT evidence on XR vs IR has short follow-up (12-24 weeks), open-label designs with high risk of measurement bias, and no long-term cardiovascular or renal outcomes . The B12 association is cross-sectional and cannot establish causality or dose-response within individuals. Conclusions would be disproven by a well-powered RCT showing a clinically meaningful HbA1c difference between XR and IR, or a longitudinal cohort showing B12 decline is unrelated to metformin dose or duration.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.